Neoplasms, Hormone-Dependent
"Neoplasms, Hormone-Dependent" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Certain tumors that 1, arise in organs that are normally dependent on specific hormones and 2, are stimulated or caused to regress by manipulation of the endocrine environment.
| Descriptor ID |
D009376
|
| MeSH Number(s) |
C04.626
|
| Concept/Terms |
Neoplasms, Hormone-Dependent- Neoplasms, Hormone-Dependent
- Neoplasms, Hormone Dependent
- Hormone-Dependent Neoplasms
- Hormone Dependent Neoplasms
- Hormone-Dependent Neoplasm
- Neoplasm, Hormone-Dependent
|
Below are MeSH descriptors whose meaning is more general than "Neoplasms, Hormone-Dependent".
Below are MeSH descriptors whose meaning is more specific than "Neoplasms, Hormone-Dependent".
This graph shows the total number of publications written about "Neoplasms, Hormone-Dependent" by people in this website by year, and whether "Neoplasms, Hormone-Dependent" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 1 | 0 | 1 |
| 1998 | 2 | 0 | 2 |
| 1999 | 1 | 0 | 1 |
| 2000 | 0 | 1 | 1 |
| 2001 | 0 | 2 | 2 |
| 2002 | 1 | 0 | 1 |
| 2003 | 2 | 1 | 3 |
| 2004 | 1 | 1 | 2 |
| 2005 | 2 | 0 | 2 |
| 2006 | 1 | 1 | 2 |
| 2009 | 0 | 1 | 1 |
| 2011 | 0 | 1 | 1 |
| 2014 | 0 | 2 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Neoplasms, Hormone-Dependent" by people in Profiles.
-
Androgen deprivation-induced NCoA2 promotes metastatic and castration-resistant prostate cancer. J Clin Invest. 2014 Nov; 124(11):5013-26.
-
Overcoming endocrine resistance due to reduced PTEN levels in estrogen receptor-positive breast cancer by co-targeting mammalian target of rapamycin, protein kinase B, or mitogen-activated protein kinase kinase. Breast Cancer Res. 2014 Sep 11; 16(5):430.
-
First-line treatment patterns and clinical outcomes in patients with HER2-positive and hormone receptor-positive metastatic breast cancer from registHER. Oncologist. 2013; 18(5):501-10.
-
Ki67 expression in the primary tumor predicts for clinical benefit and time to progression on first-line endocrine therapy in estrogen receptor-positive metastatic breast cancer. Breast Cancer Res Treat. 2012 Sep; 135(2):619-27.
-
The importance of nonpharmacogenetic factors in endocrine therapy. Pharmacogenomics. 2012 Apr; 13(6):721-8.
-
Prostate cancer stem cells. Clin Genitourin Cancer. 2012 Jun; 10(2):69-76.
-
Addition of short-term androgen deprivation therapy to dose-escalated radiation therapy improves failure-free survival for select men with intermediate-risk prostate cancer. Ann Oncol. 2012 Sep; 23(9):2346-2352.
-
A kinome-wide screen identifies the insulin/IGF-I receptor pathway as a mechanism of escape from hormone dependence in breast cancer. Cancer Res. 2011 Nov 01; 71(21):6773-84.
-
Definition of a FoxA1 Cistrome that is crucial for G1 to S-phase cell-cycle transit in castration-resistant prostate cancer. Cancer Res. 2011 Nov 01; 71(21):6738-6748.
-
Dicer-mediated upregulation of BCRP confers tamoxifen resistance in human breast cancer cells. Clin Cancer Res. 2011 Oct 15; 17(20):6510-21.